Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LeMaitre VascularLMAT +0.78%100 EV-to-EBITDA is 17.41 as of Aug. 07, 2026, which is 29% below its 10-year median of 24.53. GuruFocus rates LMAT with a GF Score™ of 100/100 and a GF Value™ of $95.26 (Modestly Undervalued). Among 512 Medical Devices & Instruments companies, LeMaitre Vascular ranks worse than 56.45% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, LeMaitre Vascular's enterprise value is $1,676.7 Mil.
LeMaitre Vascular's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $96.3 Mil. Therefore, LeMaitre Vascular's EV-to-EBITDA for today is 17.41.
The historical rank and industry rank for LeMaitre Vascular's EV-to-EBITDA or its related term are showing as below:
LMAT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.51 Med: 24.53 Max: 39.16
Current: 16.69
During the past 13 years, the highest EV-to-EBITDA of LeMaitre Vascular was 39.16. The lowest was 12.51. And the median was 24.53.
LMAT's EV-to-EBITDA is ranked worse than 56.45% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.645
vs LMAT: 16.69
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
LeMaitre Vascular's PE Ratio (TTM) for today is calculated as:
LeMaitre Vascular's share price for today is $81.45.
LeMaitre Vascular's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.850.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for LeMaitre Vascular's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, LeMaitre Vascular's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LeMaitre Vascular EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, LeMaitre Vascular's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where LeMaitre Vascular's EV-to-EBITDA falls into.
LeMaitre Vascular's current Enterprise Value is $1,676.7 Mil.
LeMaitre Vascular's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $96.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LeMaitre Vascular (LMAT) has a EV-to-EBITDA of 17.41 as of Aug. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on LeMaitre Vascular. This is 29% below median its historical median of 24.53. Over the past decade, LeMaitre Vascular's EV-to-EBITDA has ranged from 12.51 to 39.16. According to the industry distribution chart, LeMaitre Vascular ranks #289 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 56.4%.
Is LeMaitre Vascular's EV-to-EBITDA too high?
LeMaitre Vascular's current EV-to-EBITDA of 17.41 is 29% below median its 10-year median of 24.53. Over the past 10 years, this metric has ranged from a low of 12.51 to a high of 39.16. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.65. LeMaitre Vascular's value of 17.41 is 18.9% above this industry median. Based on the distribution chart, LeMaitre Vascular ranks #289 out of 512 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, LeMaitre Vascular has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LeMaitre Vascular's EV-to-EBITDA compare to PLSE and XRAY?
According to the Medical Devices & Instruments industry distribution chart, LeMaitre Vascular ranks #289 out of 512 companies for EV-to-EBITDA. This places LeMaitre Vascular in the lower half of its industry. The industry median EV-to-EBITDA is 14.65. LeMaitre Vascular's value of 17.41 is 18.9% above this benchmark. Historically, LeMaitre Vascular's own EV-to-EBITDA has ranged from 12.51 to 39.16 over the past decade. While the company's 10-year median is 24.53 vs. the industry median of 14.65, LeMaitre Vascular has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.65, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LeMaitre Vascular's current EV-to-EBITDA of 17.41 is 18.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on LeMaitre Vascular. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LeMaitre Vascular's current EV-to-EBITDA is 17.41, which is 29% below median its own 10-year median of 24.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LeMaitre Vascular stock overvalued right now?
Based on GuruFocus' analysis, LeMaitre Vascular (LMAT) is currently considered Modestly Undervalued. The stock's GF Value™ is $95.26, compared to a current price of $81.45 — trading 14.5% below its estimated fair value. The current EV-to-EBITDA is 17.41, which is 29% below median its 10-year median of 24.53 and 18.9% above the Medical Devices & Instruments industry median of 14.65. LeMaitre Vascular's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For LeMaitre Vascular (LMAT), the current EV-to-EBITDA is 17.41 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is LeMaitre Vascular (LMAT) Overvalued in 2026?
Based on GuruFocus' analysis, LeMaitre Vascular stock appears to be undervalued.
The current stock price of $81.45 is trading 14.5% below its estimated GF Value™ of $95.26.
GuruFocus considers LeMaitre Vascular to be Modestly Undervalued.
Key valuation signals for LMAT:
EV-to-EBITDA: 17.41 (29% below median its 10-year median of 24.53)
GF Value™: $95.26 vs. price of $81.45 (14.5% below fair value)
Industry Position: 18.9% above the Medical Devices & Instruments median (#289 of 512)
No single metric tells the full story. See the LMAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
100GF Score
Get the complete analysis for LMAT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LMAT has been successfully added to your 
